ACRS – aclaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Walker Neal
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Davis Hugh M.
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Kolbeck Roland Wilhelm
Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Hall Jesse Wayne
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.